CAPR (Capricor Therapeutics) 3-Year Dividend Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAPR Capricor Therapeutics Inc CAPR
24 GF Score
Price $9.40
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics 3-Year Dividend Growth Rate?

Capricor Therapeutics CAPR +1.29% 24 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CAPR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 94 Biotechnology companies, Capricor Therapeutics ranks worse than 1063828.72% on this metric.

Capricor Therapeutics's Dividends per Share for the three months ended in Jun. 2026 was $0.00.

The historical rank and industry rank for Capricor Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

CAPR's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.4
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Capricor Therapeutics's Dividend Payout Ratio for the three months ended in Jun. 2026 was 0.00. As of today, Capricor Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Capricor Therapeutics  (NAS:CAPR) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Capricor Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=0/ -0.723
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Capricor Therapeutics 3-Year Dividend Growth Rate Related Terms>


CAPR vs BLSM, ZURA, OVID: 3-Year Dividend Growth Rate Comparison

For the Biotechnology subindustry, Capricor Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics 3-Year Dividend Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's 3-Year Dividend Growth Rate falls into.


CAPR
24GF Score
Capricor Therapeutics Inc CAPR
3-Year Dividend Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Dividend Growth Rate of 0.00% mean?
Capricor Therapeutics (CAPR) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #999999 out of 94 companies in the Biotechnology industry.
Is Capricor Therapeutics' 3-Year Dividend Growth Rate too high?
Capricor Therapeutics' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Capricor Therapeutics ranks #999999 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' 3-Year Dividend Growth Rate compare to BLSM and ZURA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #999999 out of 94 companies for 3-Year Dividend Growth Rate. This places Capricor Therapeutics in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.40, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (CAPR) has a current 3-Year Dividend Growth Rate of 0.00%. The current 3-Year Dividend Growth Rate is 0.00%. Capricor Therapeutics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
24GF Score

Get the complete analysis for CAPR

3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.40
Price